These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 37366614)

  • 1. Cefepime Population Pharmacokinetics, Antibacterial Target Attainment, and Estimated Probability of Neurotoxicity in Critically Ill Patients.
    Bilal M; Zoller M; Fuhr U; Jaehde U; Ullah S; Liebchen U; Büsker S; Zander J; Babouee Flury B; Taubert M
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0030923. PubMed ID: 37366614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients.
    An G; Creech CB; Wu N; Nation RL; Gu K; Nalbant D; Jimenez-Truque N; Fissell W; Patel PC; Fishbane N; Watanabe A; Rolsma S; Kirkpatrick CMJ; Landersdorfer CB; Winokur P
    J Antimicrob Chemother; 2023 Jun; 78(6):1460-1470. PubMed ID: 37071586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO).
    Kois AK; Gluck JA; Nicolau DP; Kuti JL
    Int J Antimicrob Agents; 2022 Jul; 60(1):106603. PubMed ID: 35577257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing.
    Al-Shaer MH; Neely MN; Liu J; Cherabuddi K; Venugopalan V; Rhodes NJ; Klinker K; Scheetz MH; Peloquin CA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32601155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An optimal extended-infusion dosing of cefepime and ceftazidime in critically ill patients with continuous renal replacement therapy.
    Sember AM; LoFaso ME; Lewis SJ
    J Crit Care; 2022 Jun; 69():154011. PubMed ID: 35202996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefepime population pharmacokinetics and dosing regimen optimization in critically ill children with different renal function.
    de Cacqueray N; Hirt D; Zheng Y; Bille E; Leger PL; Rambaud J; Toubiana J; Chosidow A; Vimont S; Callot D; Chouchana L; Béranger A; Tréluyer JM; Benaboud S; Oualha M
    Clin Microbiol Infect; 2022 Oct; 28(10):1389.e1-1389.e7. PubMed ID: 35605841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.
    Rhodes NJ; Grove ME; Kiel PJ; O'Donnell JN; Whited LK; Rose DT; Jones DR; Scheetz MH
    Int J Antimicrob Agents; 2017 Sep; 50(3):482-486. PubMed ID: 28668694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics and Monte Carlo Simulation of Cefepime in Critically Ill Patients with Hospital-Acquired/Ventilator-Associated Pneumonia.
    Seo H; Kim YK; Park S; Kim HI; Lee DH
    Infect Chemother; 2023 Mar; 55(1):29-41. PubMed ID: 36450287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Al-Shaer MH; Philpott CD; Droege CA; Courter JD; Healy DP; Droege ME; Ernst NE; Mueller EW; Peloquin CA
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33722885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study.
    Chaijamorn W; Charoensareerat T; Srisawat N; Pattharachayakul S; Boonpeng A
    J Intensive Care; 2018; 6():61. PubMed ID: 30221005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis.
    An G; Creech CB; Wu N; Nation RL; Gu K; Nalbant D; Jimenez-Truque N; Fissell W; Rolsma S; Patel PC; Watanabe A; Fishbane N; Kirkpatrick CMJ; Landersdorfer CB; Winokur P
    Antimicrob Agents Chemother; 2023 Jan; 67(1):e0131222. PubMed ID: 36622154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study).
    Cheng V; Abdul-Aziz MH; Burrows F; Buscher H; Corley A; Diehl A; Jakob SM; Levkovich BJ; Pellegrino V; Que YA; Reynolds C; Rudham S; Wallis SC; Welch SA; Zacharias D; Roberts JA; Shekar K; Fraser JF
    Int J Antimicrob Agents; 2021 Dec; 58(6):106466. PubMed ID: 34688834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study.
    Hartman SJF; Upadhyay PJ; Hagedoorn NN; Mathôt RAA; Moll HA; van der Flier M; Schreuder MF; Brüggemann RJ; Knibbe CA; de Wildt SN
    Clin Pharmacokinet; 2021 Oct; 60(10):1361-1372. PubMed ID: 34036552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
    Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB
    Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal antipseudomonal ꞵ-lactam drug dosing recommendations in critically-ill Asian patients receiving CRRT.
    Jang SM; Lewis SJ; Rhie SJ
    J Crit Care; 2022 Dec; 72():154172. PubMed ID: 36270240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
    Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
    J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
    Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically Ill Patients.
    Heffernan AJ; Sime FB; Kumta N; Wallis SC; McWhinney B; Ungerer J; Wong G; Joynt GM; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0218921. PubMed ID: 35575578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.